N,N'-二乙酰基-L-胱氨酸结构式
|
常用名 | N,N'-二乙酰基-L-胱氨酸 | 英文名 | N,N'-Diacetyl-L-cystine |
---|---|---|---|---|
CAS号 | 5545-17-5 | 分子量 | 324.374 | |
密度 | 1.5±0.1 g/cm3 | 沸点 | 715.5±60.0 °C at 760 mmHg | |
分子式 | C10H16N2O6S2 | 熔点 | 55-72ºC | |
MSDS | N/A | 闪点 | 386.5±32.9 °C |
N,N'-二乙酰基-L-胱氨酸用途N,N'-diacetyl-L-cystine (DiNAC) 是一种具有免疫调节特性的 N-乙酰基半胱氨酸的二硫二聚体。N,N'-diacetyl-L-cystine 是啮齿类动物中接触敏感/迟发型超敏反应的有效口服活性调节剂。N,N'-diacetyl-L-cystine 在高脂血症兔 (WHHL) 中也具有抗动脉粥样硬化的作用。 |
中文名 | N,N’-二乙酰-L-胱氨酸 |
---|---|
英文名 | (ac-cys-oh)2 |
中文别名 | N,N'-二乙酰-L-胱氨酸 |
英文别名 | 更多 |
描述 | N,N'-diacetyl-L-cystine (DiNAC) 是一种具有免疫调节特性的 N-乙酰基半胱氨酸的二硫二聚体。N,N'-diacetyl-L-cystine 是啮齿类动物中接触敏感/迟发型超敏反应的有效口服活性调节剂。N,N'-diacetyl-L-cystine 在高脂血症兔 (WHHL) 中也具有抗动脉粥样硬化的作用。 |
---|---|
相关类别 | |
靶点 |
Immunomodulator[1] |
体内研究 | N,N'-二乙酰-L-胱氨酸(DiNAC;0-973.11μg/kg;口服给药;每日;12周;WHHL兔)治疗减少50%胸主动脉动脉粥样硬化,而不影响血浆脂质水平[1]。动物模型:雄性遗传性高脂血症兔(WHHL)兔(10-22周)[1]剂量:0μg/kg,9.73μg/kg或973.11μg/kg给药:口服给药;每日;12周结果:减少50%胸主动脉粥样硬化,不影响血浆脂质水平。 |
参考文献 |
密度 | 1.5±0.1 g/cm3 |
---|---|
沸点 | 715.5±60.0 °C at 760 mmHg |
熔点 | 55-72ºC |
分子式 | C10H16N2O6S2 |
分子量 | 324.374 |
闪点 | 386.5±32.9 °C |
精确质量 | 324.044983 |
PSA | 183.40000 |
LogP | 0.46 |
外观性状 | 白色粉末 |
蒸汽压 | 0.0±5.0 mmHg at 25°C |
折射率 | 1.583 |
储存条件 | -15°C |
稳定性 | Moisture Sensitive |
海关编码 | 29225090 |
---|
~98% N,N'-二乙酰基-L-胱氨酸 5545-17-5 |
文献:Oba, Makoto; Tanaka, Kazuhito; Nishiyama, Kozaburo; Ando, Wataru Journal of Organic Chemistry, 2011 , vol. 76, # 10 p. 4173 - 4177 |
~0% N,N'-二乙酰基-L-胱氨酸 5545-17-5 |
文献:Stamler, Jonathan S.; Loscalzo, Joseph Analytical Chemistry, 1992 , vol. 64, # 7 p. 779 - 785 |
~% N,N'-二乙酰基-L-胱氨酸 5545-17-5 |
文献:Journal of Biological Chemistry, , vol. 94, p. 244 Archives of Biochemistry, , vol. 18, p. 379 |
~22% N,N'-二乙酰基-L-胱氨酸 5545-17-5 |
文献:Watzig; Dette; Aigner; Wilschowitz Pharmazie, 1994 , vol. 49, # 4 p. 249 - 252 |
~% N,N'-二乙酰基-L-胱氨酸 5545-17-5 |
文献:Inorganic chemistry, , vol. 39, # 8 p. 1728 - 1734 |
~% N,N'-二乙酰基-L-胱氨酸 5545-17-5 |
文献:Biochemical Journal, , vol. 25, p. 619 Rikagaku Kenkyusho Iho, , vol. 8, p. 647,650 Chem. Zentralbl., , vol. 100, # II p. 2770 |
~% N,N'-二乙酰基-L-胱氨酸 5545-17-5 |
文献:Biochemical Journal, , vol. 25, p. 619 Rikagaku Kenkyusho Iho, , vol. 8, p. 647,650 Chem. Zentralbl., , vol. 100, # II p. 2770 |
~% N,N'-二乙酰基-L-胱氨酸 5545-17-5 |
文献:Photochemistry and Photobiology, , vol. 71, # 3 p. 273 - 280 |
~% N,N'-二乙酰基-L-胱氨酸 5545-17-5 |
文献:Canadian Journal of Chemistry, , vol. 76, # 6 p. 789 - 794 |
N,N'-二乙酰基-L-胱氨酸上游产品 8 | |
---|---|
N,N'-二乙酰基-L-胱氨酸下游产品 3 | |
Influence of N,N'-diacetyl-L-cystine on D-galactosamine/lipopolysaccharide induced immunological liver failure in mice.
Yao Xue Xue Bao 39(10) , 782-6, (2004) To study the therapeutic effects of N,N'-diacetyl-L-cystine (DiNAC) on immunological liver failure.Serum ALT, AST and T cell subsets in peripheral blood of the experimental animals during the trial pe... |
|
Immunomodulation with DiNAC-- a new approach to the treatment of atherosclerosis?
Expert Opin. Investig. Drugs 11(5) , 717-20, (2002) Not all antioxidants reduce atherosclerosis. This may be because atherosclerosis has an autoimmune, inflammatory pathogenesis. As probucol is both an antioxidant and an immunomodulatory drug, it may b... |
|
The new oral immunomodulating drug DiNAC induces brachial artery vasodilatation at rest and during hyperemia in hypercholesterolemic subjects, likely by a nitric oxide-dependent mechanism.
Atherosclerosis 196(1) , 275-82, (2008) To investigate if the immunomodulator drug DINAC (1) affects arterial dimensions in asymptomatic patients with hypercholesterolemia, (2) has effects on leucocyte markers of inflammation and (3) has in... |
N,N`-Diacetyl-L-cystine |
N,N'-Diacetyl-L-cystine |
N,N'-diacetyl-cystine |
N-acetyl-L-cystine |
ACETYL-L-CYSTINE |
DiNAC |
L-Cystine, N,N'-diacetyl- |
Cystine, N,N'-diacetyl-, L- |
diacetylcysteine |
L-Cystine,N,N'-diacetyl |
N,N''-Diacetyl-L-cysteine |
N-ACETYL CYSTINE |